Neurologic disease burden in treated HIV/AIDS predicts survival: A population-based study

Neurology

Volumn 75, Issue 13, 2010, Pages 1150-1158

  Vivithanaporn, P ^a,b   Heo, G ^a   Gamble, J ^a   Krentz, H B ^c   Hoke, A ^d   Gill, M J ^c,e,f   Power, C ^a,c,e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Southern Alberta Clinic   (Canada)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANADA; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; CONTROLLED STUDY; DISTAL SENSORY POLYNEUROPATHY; EPILEPSY; FEMALE; HEADACHE; HEALTH PROGRAM; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONONEUROPATHY; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; MYOPATHY; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; SEIZURE; SURVIVAL TIME; VIRUS LOAD; HEALTH CARE PLANNING; INCIDENCE; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

ADULT; COMMUNITY HEALTH PLANNING; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 77957969916     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f4d5bb     Document Type: Article

References (34)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-29.
2. Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 2005;32:247-260.
3. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8(suppl 2):115-121.
4. McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003;9:205-221.
5. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003;17:1539-1545.
6. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008; 197(suppl 3):S294-S306.
7. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005;40:148-157.
8. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neu-rocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol 2005;11:265-273.
9. Smyth K, Affandi JS, McArthur JC, et al. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med 2007;8:367-373.
10. Pettersen JA, Jones G, Worthington C, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitormediated neurotoxicity. Ann Neurol 2006;59:816-824.
11. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000;69:376-380.
12. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52:607-613.
13. Valcour V, Yee P, Williams AE, et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection: The Hawaii Aging with HIV Cohort. J Neurovirol 2006;12:387-391.
14. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915-1921.
15. Mocroft A, Sterne JA, Egger M, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009;48: 1138-1151.
16. Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses 2005; 21:706-713.
17. Power C, Boisse L, Rourke S, Gill MJ. NeuroAIDS: an evolving epidemic. Can J Neurol Sci 2009;36:285-295.
18. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection: report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778-785.
19. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder: The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Neurology 1996; 47:1247-1253.
20. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
21. The Burden of Neurological Diseases, Disorders, and Injuries in Canada. Ottawa: Canadian Institute of Health Information; 2007.
22. Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med 2009;10:918-929.
23. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24:1243-1250.
24. Kellinghaus C, Engbring C, Kovac S, et al. Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure 2008;17:27-33.
25. Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifo-cal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009;199:77-83.
26. Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009;48:1459-1466.
27. Evers S, Wibbeke B, Reichelt D, Suhr B, Brilla R, Husst-edt I. The impact of HIV infection on primary headache: unexpected findings from retrospective, cross-sectional, and prospective analyses Pain 2000;85:191-200.
28. Mirsattari SM, Power C, Nath A. Primary headaches in HIV-infected patients. Headache 1999;39:3-10.
29. Cardoso F. HIV-related movement disorders: epidemiology, pathogenesis and management. CNS Drugs 2002;16:663-668.
30. Tambussi G, Gori A, Capiluppi B, et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis 2000;30:962-965.
31. Madden LJ, Zandonatti MA, Flynn CT, et al. CD8+ cell depletion amplifies the acute retroviral syndrome. J Neu-rovirol 2004;10(suppl 1):58-66.
32. Stebbing J, Bower M, Mandalia S, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clin Exp Immunol 2006;145:271-276.
33. Sanchez-Ramon S, Bellon JM, Resino S, et al. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children. Pediatrics 2003;111:E168-175.
34. Schellens IM, Borghans JA, Jansen CA, et al. Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time. PLoS One 2008;3:e2745.